Table 2:
Treatment Characteristics of Older Men and Women Hospitalized with AMI: Medical Therapies, Interventions, and In-hospital Outcomes (N=3041)
| NSTEMI(n=2244) | STEMI (n=797) | |||||
|---|---|---|---|---|---|---|
| Treatment Characteristics | Men (n=1276) | Women (n = 968) | p-value* | Men (n=419) | Women (n = 378) | p-value* |
| Medical Therapies on Admission (%) | N (%) | N (%) | ||||
| Aspirin | 979 (76.7%) | 740 (76.4%) | 0.77 | 279 (66.6%) | 234 (61.9%) | 0.16 |
| P2Y12 Inhibitor | 688 (53.9%) | 503 (52.0%) | 0.82 | 369 (88.1%) | 329 (87.0%) | 0.94 |
| Clopidogrel | 593 (46.5%) | 431 (44.5%) | 233 (55.6%) | 208 (55.0%) | ||
| Ticlopidine | 0 | 0 | 1 (0.2%) | 2 (0.5%) | ||
| Prasugrel | 10 (0.8%) | 7 (0.7%) | 13 (3.1%) | 13 (3.4%) | ||
| Ticagrelor | 85 (6.7%) | 65 (6.7%) | 122 (29.1%) | 106 (28.0%) | ||
| Anticoagulant use (intravenous or subcutaneous) | 1013 (79.4%) | 777 (80.3%) | 0.61 | 373 (89.0%) | 340 (90.0%) | 0.67 |
| GpIIb/IIIa inhibitor | 55 (4.3%) | 26 (2.7%) | 0.04 | 111 (26.5%) | 91 (24.1%) | 0.43 |
| UFH | 869 (68.1%) | 627 (64.8%) | 0.10 | 331 (79.0%) | 299 (79.1%) | 0.97 |
| LMWH | 197 (15.4%) | 186 (19.2%) | 0.02 | 39 (9.3%) | 44 (11.6%) | 0.28 |
| Bivalirudin | 78 (6.1%) | 63 (6.5%) | 0.70 | 97 (23.2%) | 80 (21.2%) | 0.50 |
| Statin | 959 (75.2%) | 684 (70.7%) | 0.02 | 361 (86.2%) | 295 (78.0%) | <0.01 |
| Beta blocker | 1007 (78.92%) | 0764 (78.93%) | 0.96 | 337 (80.4%) | 282 (74.6%) | 0.05 |
| ACE-I or ARB | 606 (47.5%) | 526 (54.3%) | <0.01 | 172 (41.1%) | 169 (44.7%) | 0.34 |
| Interventions (%) | ||||||
| Coronary angiography | 1042 (81.7%) | 755 (78.0%) | 0.03 | 411 (98.1%) | 362 (95.8%) | 0.06 |
| PCI | 605 (47.4%) | 437 (45.1%) | 0.29 | 375 (89.5%) | 321 (84.9%) | 0.05 |
| CABG | 214 (16.8%) | 105 (10.9%) | <0.001 | 28 (6.7%) | 15 (4.0%) | 0.09 |
| Revascularization (PCI or CABG) | 811 (63.6%) | 538 (55.6%) | <0.001 | 391 (93.3%) | 330 (87.3%) | 0.01 |
| Coronary angiography (%) | (N=1042) | (N=755) | (N = 411) | (N = 362) | ||
| Obstructive coronary disease (%) | <0.001 | 0.02 | ||||
| None | 28 (2.7%) | 71 (9.4%) | 0 | 5 (1.4%) | ||
| 1 vessel | 171 (16.4%) | 212 (28.1%) | 138 (33.6%) | 145 (40.1%) | ||
| 2 vessels | 231 (22.2%) | 179 (23.7%) | 141 (34.3%) | 124 (34.3%) | ||
| 3 vessels or left main | 612 (58.7%) | 293 (38.8%) | 132 (32.1%) | 88 (24.3%) | ||
| LVEF % from echo | 0.001 | <0.01 | ||||
| >=50% | 609 (47.7%) | 525 (54.2%) | 200 (47.7%) | 203 (53.7%) | ||
| 40–50% | 230 (18.0%) | 161 (16.6%) | 128 (30.5%) | 81 (21.4%) | ||
| 30–40% | 179 (14.0%) | 102 (10.5%) | 55 (13.1%) | 66 (17.5%) | ||
| <30% | 112 (8.8%) | 58 (6.0%) | 33 (7.9%) | 20 (5.3%) | ||
| In-hospital Outcomes | ||||||
| Hospital Length of Stay | 6.6 (6.14) | 6.2 (5.50) | 0.09 | 4.6 (4.06) | 4.9 (3.80) | 0.26 |
| Discharge to home (%) | 1023 (80.2%) | 719 (74.3%) | <0.001 | 363 (86.6%) | 312 (82.5%) | 0.11 |
*
based on chi-squared or Fisher’s Exact test for categorical variables and the T-test or Wilcoxon rank sum test for continuous variables.
Abbreviations: IV=intravenous, SQ=subcutaneous, UFH=unfractionated heparin, LMWH=low molecular weight heparin, ACE-I=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker, LVEF=Left ventricular ejection fraction, PCI=Percutaneous Coronary Intervention, CABG=coronary artery bypass grafting